Providing access to novel personalised medicines in the Netherlands. Is pharmacy compounding the solution?

Data accompanying a qualitative study about the possibility & desirability of compounding (officinal and magistral pharmacy preparation) of novel personalised treatments in the Netherlands. Research question: What are the boundaries and consequences of using compounding as a patient access pathway to novel personalised treatments in the Netherlands?

The dataset contains 18 pseudonymized transcripts of semi-structured interviews with 19 Dutch stakeholders, including government, regulatory, legal, reimbursement, pharmacist, prescriber and patient perspectives. An interview guide & scenario were used to structure the interviews. The hypothetical scenario was varied to explore stakeholders’ interpretations of the appropriateness and boundaries of pharmacy preparation.

Data sharing: Interview transcripts have been pseudonymized by removing direct identifiable information, such as name, workplace etc. However, individuals may still risk being identifiable due to contextual information. The qualitative interview data are therefore not openly available. Data may be accessed for re-use in scientific research upon request, with the involvement of the original research team, and subject to ethical and data protection requirements. Upon a request to access the data, a data transfer agreement will be drafted specifying the terms of use of the data to protect data in accordance to the GDPR. Additional research records are stored at the internal archive of the Division of Pharmacoepidemiology and Clinical Pharmacology, and can be accessed to facilitate data re-use.